Best of two worlds: combining optical tweezers with time-resolved confocal microscopy
PicoQuant and Ionovation now offer an integrated platform that combines microscopy and force spectroscopy
Berlin (Germany), 13 February 2018 – As a joint development, PicoQuant and Ionovation combined time-resolved microscopy and optical tweezers in a single system. Both instruments retain their individual functionalities but can also be used together , thus enabling customers to carry out time-resolved fluorescence microscopy (e.g., fluorescence lifetime imaging) on trapped objects such as cells.
PicoQuant and Ionovation will showcase the features of this combined system at the 62nd Biophysical Society Meeting in San Francisco (February 17- 21, 2018).
PicoQuant‘s MicroTime 200 platform is the most flexible and extensible high-end research tool for time-resolved fluorescence microscopy requiring single molecule sensitivity. The system is an excellent choice for many methods, including Pulsed Interleaved Excitation (PIE), Förster Resonance Transfer (FRET), Stimulated Emission Depletion (STED) super-resolution microscopy, Fluorescence (Lifetime) Correlation Spectroscopy (F(L)CS), and anisotropy measurements.
Ionovation’s PicoTweezers system is a compact, robust trapping and force measurement device based on the “optical tweezers” concept which is equipped with real-time video detection. In contrast to common optical tweezers systems, PicoTweezers has no spatial restrictions and is compatible to all sample carriers. The system is well suited for molecular interaction studies, force spectroscopy, cell trapping, rheology and many other applications.
PicoQuant is a leading research and development company specializing in optoelectronics, which was founded in 1996. The company, based in the science and technology park of Berlin-Adlershof, Germany, is a worldwide leader in the field of single photon counting applications. The product portfolio encompasses picosecond pulsed diode lasers and LEDs, photon counting instrumentation, fluorescence lifetime spectrometers, FLIM and FCS upgrade kits for laser scanning microscopes as well as time-resolved confocal and super-resolution microscopes. Since April 2008 Sales and Support in North America is handled by PicoQuant Photonics North America Inc. The PicoQuant group employs currently around 80 people.
Founded in 2004, Ionovation represents a wealth of experience in the development, integration and automation of complementary technical and scientific systems in the fields of life-sciences. Ionovation's unique combination of modern analytical methods with a broad range of microscopy techniques translates into a product line ranging from automated lipid bilayer (BLM) workstations to robust and easy to use optical tweezers for unprecedented force spectroscopy applications as well as industry compliant 3D-cell culture and Organ-on-Chip supply systems.
Dr. Karsten Gall
Tel.: +49 5402 968 979 30
February 17 - 21, 2018 | San Francisco
Just like every year since 2008 Ionovation will be presenting instruments and tools for biomembrane research and optical tweezers at the Biophysical Meeting.
If you find your way to one of the most exciting cities in the world visit us at booth #609 for a chat with our experts about your research and/or our instruments .
This years special:
- The worlds most flexible optical tweezers system, "Ionovation PicoTweezers" will be presented in cooperation with PicoQuant (booth #418). The combination of the PicoTweezers with PicoQuant's MicroTime 200 and other high-end microscopes will be demonstrated. Meet the experts from PicoQuant and Ionovation and discuss your most challenging needs for your optical applications with us.
By the end of 2017 Ionovation has moved to a more spacious and fancy new location. Find us in the "Innovationsforum Bissendorf" near Osnabrück.
The new Address is:
Gewerbepark 9 - 11
+49 5402 968 979 30
+49 5402 968 979 39
Ionovation receives SME Instrument Phase I funding for IonoChem drug delivery system
Osnabrück, August 10, 2015
Ionovation GmbH, a biomembrane research company located in Osnabrück, Germany, was awarded a grant in the highly competitive Horizon2020 SME Instrument Phase I scheme for its innovative trans-membrane drug delivery technology IonoChem.
"In the SME Instrument scheme only the most promising and disruptive technologies are chosen for funding", says Dr. Karsten Gall, CEO of Ionovation GmbH. "We feel very honored; the positive feedback from Brussels shows that it was worth putting in the extra effort for developing a promising new technology that will help us grow beyond our current product line of biomembrane analytical products and services."
With the IonoChem method drugs can be modified to pass through cellular membranes more easily. "Many drugs do not enter cells in sufficient quantities to be effective", explains Professor Helmut Rosemeyer, University of Osnabrück and one of the inventors of the IonoChem method. "With IonoChem we add a lipophilic tail directly to the drug molecule which makes it pass through the membrane more easily. We think that this is a highly promising drug delivery technology especially for RNA and DNA drugs which might have the potential to speed up clinical application of this new class of drugs."
Within this 6 months project Ionovation GmbH will analyze customer needs in depth, refine the business model and will partner with a contract manufacturer as part for preparing for the SME Instrument Phase II grant scheme application.
About Ionovation GmbH
Founded in 2004, Ionovation represents a wealth of experience in the development and application of modern electrophysiological and fluorescence methods, combined with recent additions in the chemical modification of membrane-related molecules. Ionovation's IonoTec product line offers instrumentation, consumables, and services centered on membrane biophysics with instruments for the automated, reproducible, and hence routine-oriented generation of lipid bilayers for the analysis of biomembrane related phenomena. The IonoChem technology offers a broad spectrum of lipids for the lipophilisation of active pharmaceutical ingredients. It comprises various classes of lipids ranging from natural plant origin, like isoprenoids, to functionalised mono- and double tailed natural or (semi-)synthetic lipids. Ionovation GmbH holds the central patent family PCT/EP2013/069936 for this technology.